ERNEST HAWK to Adenomatous Polyposis Coli
This is a "connection" page, showing publications ERNEST HAWK has written about Adenomatous Polyposis Coli.
Connection Strength
0.526
-
Chemoprevention in hereditary colorectal cancer syndromes. Cancer. 1999 Dec 01; 86(11 Suppl):2551-63.
Score: 0.159
-
The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol. 2010 Jun; 105(6):1437-43.
Score: 0.081
-
Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev. 2004 Jun; 13(6):920-7.
Score: 0.054
-
Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res. 2004 Apr 15; 64(8):2904-9.
Score: 0.054
-
Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol. 2002 Feb; 7(1):2-26.
Score: 0.046
-
The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000 Jun 29; 342(26):1946-52.
Score: 0.041
-
Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res. 2000 Jan; 6(1):78-89.
Score: 0.040
-
Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol. 1999; 470:45-53.
Score: 0.037
-
A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002 Jun; 50(6):857-60.
Score: 0.012